Portfolio
Teiko
“Teiko has developed an immune profiling platform using mass cytometry to revolutionize pre-clinical discovery and pharmaceutical development. Unlike conventional immune monitoring techniques like flow cytometry, Teiko uses metal-conjugated antibodies to profile >1 trillion unique cellular phenotypes in a single patient sample, a 1-billion-fold increase over flow. The end-to-end solution removes barriers to use mass cytometry analysis, to more effectively identify promising drug targets for pre-clinical development and biomarkers and cell signatures to promote clinical trial success towards approval.”
Founders: Ramji Srinivasan & Matt Spitzer
Location: Salt Lake City, Utah
Category: Life Sciences
Company Stage: Series A
Co-Investors: HOF Capital, Founders Fund (Path Finder), GFC, Civilization Ventures, amongst others.
